Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 5/20 | 0.48 |
| ▸ | NPY1R | P25929 | 4/20 | 0.48 |
| ▸ | NPY2R | P49146 | 3/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565142 | 0.94 | CHRNA1 (0.53) | ERAP2LNPEPCHRNA1CHRNGCHRNB1 | |
| SCHEMBL30523240 | 0.93 | LNPEP (0.57) | ERAP2LNPEPNPY4RNPY1RNPY2R | |
| SCHEMBL30565177 | 0.92 | NPY4R (0.51) | ERAP2LNPEPNPY4RNPY1RNPY2R | |
| SCHEMBL29406246 | 0.92 | ERAP2 (0.55) | ERAP2LNPEPKISS1R | |
| SCHEMBL29405927 | 0.90 | LNPEP (0.52) | ERAP2LNPEP | |
| SCHEMBL29404204 | 0.90 | GNPAT (0.53) | ERAP2LNPEPCHRNA1CHRNGCHRNB1 | |
| SCHEMBL29403366 | 0.89 | LNPEP (0.52) | ERAP2LNPEPNPY4RNPY1RNPY2R | |
| SCHEMBL29405428 | 0.89 | LNPEP (0.55) | ERAP2LNPEP | |
| SCHEMBL30565152 | 0.89 | MMP2 (0.52) | ERAP2LNPEPKISS1R | |
| SCHEMBL31253372 | 0.89 | NPY4R (0.55) | ERAP2LNPEPNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619046-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | Genome & Company, Inc. (KR) | 2025-09-24 | — | — | EP | claimed |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | claimed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | claimed |
| WO-2024107014-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | GENOME AND COMPANY (KR) | 2024-05-23 | — | — | WO | claimed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4619046-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | Genome & Company, Inc. (KR) | 2025-09-24 | — | — | EP | disclosed |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | disclosed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024107014-A1 | ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE | GENOME AND COMPANY (KR) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | FCER2, FCGR2A, FCGR1A | ERAP2 830/4885LNPEP 150/4885CHRNA1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.